Biocon Launches Affordable Bone Therapy Biosimilars

  Published 10 months ago

Biocon launches Bosanya and Aukelso biosimilars, expanding affordable osteoporosis and cancer bone therapies for patients.

  • Bosanya (60 mg/mL) treats postmenopausal osteoporosis, glucocorticoid‑induced loss; Aukelso (120 mg) prevents skeletal events in multiple myeloma
  • Both products received provisional interchangeability, allowing pharmacy‑level substitution under state regulations for greater patient access
  • Denosumab US sales hit $5 billion in 2024; Biocon aims to provide cheaper alternatives for patients

You might like these

India August 2025 Auto Sales Snapshot

AVT03 Gains EMA Positive Opinion

Indian Shares Mixed Amid U.S. Tariff Uncertainty, Consumer Stocks Rise

NHAI Unveils 'Asset Monetization Strategy' to Boost Road Infra PPPs

Fitch Holds India Rating Amid Debt

Jupiter Wagons Bags ₹242 Cr Order

Ola Electric Plans Major Fundraise

News that matters the most ⚡